[go: up one dir, main page]

EP1434881A4 - Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer - Google Patents

Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer

Info

Publication number
EP1434881A4
EP1434881A4 EP02766297A EP02766297A EP1434881A4 EP 1434881 A4 EP1434881 A4 EP 1434881A4 EP 02766297 A EP02766297 A EP 02766297A EP 02766297 A EP02766297 A EP 02766297A EP 1434881 A4 EP1434881 A4 EP 1434881A4
Authority
EP
European Patent Office
Prior art keywords
methods
cancer
modulators
diagnosis
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02766297A
Other languages
German (de)
English (en)
Other versions
EP1434881A2 (fr
Inventor
Daniel Afar
Natasha Aziz
Kurt C Gish
Peter A Hevezi
David H Mack
Keith E Wilson
Albert Zlotnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Priority to EP06007721A priority Critical patent/EP1721977A3/fr
Publication of EP1434881A2 publication Critical patent/EP1434881A2/fr
Publication of EP1434881A4 publication Critical patent/EP1434881A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP02766297A 2001-09-17 2002-09-17 Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer Withdrawn EP1434881A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06007721A EP1721977A3 (fr) 2001-09-17 2002-09-17 Méthodes de diagnostic du cancer, compositions et méthodes de criblage des modulateurs du cancer

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US32346901P 2001-09-17 2001-09-17
US323469P 2001-09-17
US32388701P 2001-09-20 2001-09-20
US323887P 2001-09-20
US35066601P 2001-11-13 2001-11-13
US350666P 2001-11-13
US35514502P 2002-02-08 2002-02-08
US35525702P 2002-02-08 2002-02-08
US355257P 2002-02-08
US355145P 2002-02-08
US37224602P 2002-04-12 2002-04-12
US372246P 2002-04-12
PCT/US2002/029560 WO2003025138A2 (fr) 2001-09-17 2002-09-17 Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP06007721A Division EP1721977A3 (fr) 2001-09-17 2002-09-17 Méthodes de diagnostic du cancer, compositions et méthodes de criblage des modulateurs du cancer

Publications (2)

Publication Number Publication Date
EP1434881A2 EP1434881A2 (fr) 2004-07-07
EP1434881A4 true EP1434881A4 (fr) 2005-10-26

Family

ID=27559718

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02766297A Withdrawn EP1434881A4 (fr) 2001-09-17 2002-09-17 Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer

Country Status (5)

Country Link
EP (1) EP1434881A4 (fr)
JP (1) JP2005518782A (fr)
AU (1) AU2002330039A1 (fr)
CA (1) CA2459219A1 (fr)
WO (1) WO2003025138A2 (fr)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098481A2 (fr) 2000-06-16 2001-12-27 Biogen, Inc. Elements de regulation renale et leurs procedes d'utilisation
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
NZ530457A (en) 2001-06-01 2007-12-21 Biogen Idec Inc Molecules and methods for inhibiting shedding of KIM-1
WO2003027321A2 (fr) * 2001-09-24 2003-04-03 University Of Aarhus Methodes de diagnostic et de traitement de maladies associees a une expression alteree de neurogranine
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DE60220621T2 (de) 2001-11-09 2008-03-06 Proteologics, Inc. Posh Nukleinsäure, Polypeptide und darauf bezogene Verfahren
CA2479732A1 (fr) * 2002-03-19 2003-10-02 Curagen Corporation Polypeptides therapeutiques, acides nucleiques codant pour ceux-ci et methodes d'utilisation associees
WO2003087408A2 (fr) * 2002-04-05 2003-10-23 University Court Of The University Of Edinburgh Genes associes a la schizophrenie
US20040121362A1 (en) 2002-06-20 2004-06-24 Whitney Gena S. Identification and modulation of a G-protein coupled receptor (GPCR), RAI-3, associated with chronic obstructive pulmonary disease (COPD) and NF-kappaB and E-selectin regulation
GB0215224D0 (en) * 2002-07-01 2002-08-14 Inpharmatica Ltd Protein
EP1578762A4 (fr) * 2002-11-12 2006-08-02 Wyeth Corp Nouveau gene sensible pth
CA2512138C (fr) 2002-12-30 2013-07-16 Biogen Idec Ma Inc. Antagonistes de la molecule-1 associee a une lesion renale et leur utilisation pour moduler le systeme immunitaire
JP4462964B2 (ja) * 2003-03-10 2010-05-12 第一三共株式会社 癌特異的抗原を標的とした抗体
EP1615991A4 (fr) 2003-04-03 2007-12-19 Bristol Myers Squibb Co Polynucleotide codant un nouveau variant d'epissage p2x7 humain appele hbmyp2x7v
EP1923401A3 (fr) * 2003-04-14 2008-08-20 Novartis AG Expression génétique associée avec la différenciation des ostéoblastes
WO2004099782A2 (fr) * 2003-05-05 2004-11-18 Bayer Healthcare Ag Approche diagnostique et therapeutique des maladies associees au recepteur gpr39 (gpr39) couple a une proteine g
WO2005001049A2 (fr) * 2003-06-06 2005-01-06 Diadexus, Inc. Compositions, variants d'epissage et procedes associes a des genes et proteines ovariens specifiques
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
PT2489364E (pt) 2003-11-06 2015-04-16 Seattle Genetics Inc Compostos de monometilvalina conjugados com anticorpos
US20050153352A1 (en) * 2004-01-09 2005-07-14 Stanley Chang Cancer specific gene MG20
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
GB0404209D0 (en) * 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
WO2005085860A2 (fr) * 2004-02-27 2005-09-15 Institut Curie Nouveaux marqueurs de proliferation en pratique clinique et leur utilisation pour le pronostic ou diagnostic du cancer
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
WO2005103291A1 (fr) 2004-04-27 2005-11-03 Takeda Pharmaceutical Company Limited Nouveau ligand de protéine de récepteur conjuguée à une protéine g et utilisation de celui-ci
US20080166357A1 (en) * 2004-05-11 2008-07-10 Stefan Golz Diagnostics and Therapeutics for Diseases Associated with Dipeptidyl-Peptidase 6 (Dpp6)
EP2286844A3 (fr) 2004-06-01 2012-08-22 Genentech, Inc. Conjugués anticorps-médicament et procédés
PL1771474T3 (pl) 2004-07-20 2010-07-30 Genentech Inc Inhibitory białka angiopoetyno-4-podobnego, kombinacje i ich zastosowanie
RU2380411C2 (ru) 2004-07-20 2010-01-27 Дженентек, Инк. Способ ингибирования пролиферации гепатоцитов, способ ингибирования клеточной адгезии гепатоцитов и способ ингибирования биологической активности angptl4 в гепатоцитах или предшественниках гепатоцитов
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
CA2599967C (fr) 2005-03-02 2014-10-21 Biogen Idec Ma Inc. Anticorps kim-1 utilises dans le traitement des etats induits par th2
MX2007012909A (es) * 2005-04-18 2008-03-14 Trinity College Dublin Receptor tipo toll 14 (tlr14) y uso del mismo.
US7799519B2 (en) * 2005-07-07 2010-09-21 Vanderbilt University Diagnosing and grading gliomas using a proteomics approach
CN101415325A (zh) * 2005-11-29 2009-04-22 内华达肿瘤研究所 用于治疗和诊断与骨髓增生异常综合征(mds)相关的增殖性病症的sall4的靶向
BRPI0619582A2 (pt) 2005-12-08 2012-12-11 Medarex Inc anticorpo monoclonal humano isolado ou uma porção de ligação de antigéno do mesmo, composição, imonuconjugado, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, e, métodos para preparar um anticorpo anti-ptk7 e para tratar ou prevenir uma doença
AU2007254005B2 (en) 2006-02-10 2012-11-29 Genentech, Inc. Anti-FGF19 antibodies and methods using same
US20090220504A1 (en) 2006-03-21 2009-09-03 Anan Chuntharapai Combinatorial therapy
WO2008054534A2 (fr) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Systèmes de criblage utilisant le rtp801
EP2026843A4 (fr) 2006-06-09 2011-06-22 Quark Pharmaceuticals Inc Utilisations thérapeutiques d'inhibiteurs de rtp801l
US7851144B2 (en) 2006-08-18 2010-12-14 The University Of Washington Compositions and methods for detecting cancer
GB0620695D0 (en) * 2006-10-18 2006-11-29 Opsona Therapeutics Composition and methods for the treatment of nurdegenerative disease
GB0620705D0 (en) 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
EP1932854A1 (fr) * 2006-12-15 2008-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides s'apparentant à une protéine de membrane associée à un lysosome (LAMP), ligands correspondants et leur utilisation dans le cadre de la détection et de la purification de cellules dendritiques plasmacytoïdes humaines
WO2009014565A2 (fr) * 2007-04-26 2009-01-29 Ludwig Institute For Cancer Research, Ltd. Procédés pour le diagnostic et le traitement des astrocytomes
KR101167392B1 (ko) 2007-07-27 2012-07-19 이매틱스 바이오테크놀로지스 게엠베하 종양 관련 펩티드의 조성물 및 관련된 항암 백신
EP2188310B1 (fr) 2007-08-03 2017-02-08 Genentech, Inc. Antagonistes humanisés anti-fgf19 et procédés d'utilisation associés
WO2009032292A1 (fr) 2007-09-06 2009-03-12 Case Western Reserve University Procédés de diagnostic et de traitement de cancers
CL2008002856A1 (es) 2007-09-26 2009-01-16 Genentech Inc Anticuerpo novedoso (anticuerpo anti-integrina a5b1; mol}ecula de ácido nucleico que lo codifica; vector y célula huesped; método de producción; composición farmacéutica que lo comprende; su uso para inhibir la angiogénesis y/o permeabilidad vascular y cáncer entre otras patologías; y método de detección de la integrina a5b1).
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
EP2313435A4 (fr) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3)
WO2010009124A2 (fr) 2008-07-15 2010-01-21 Genentech, Inc. Conjugués de dérivés d’anthracycline, procédé de préparation associé et utilisation comme composés antitumoraux
US20110160085A1 (en) * 2008-08-25 2011-06-30 Katherine Li Biomarkers for anti-tnf treatment in ulcreative colitis and related disorders
WO2010047310A1 (fr) 2008-10-20 2010-04-29 大日本住友製薬株式会社 Peptide d’antigène tumoral et utilisation de celui-ci
EP2373690B1 (fr) 2008-12-08 2015-02-11 Compugen Ltd. Anticorps spécifiques du tmem154
AU2014201027B2 (en) * 2008-12-08 2015-11-19 Compugen Ltd. FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
AU2010229479B2 (en) 2009-03-25 2013-03-28 Genentech, Inc. Novel anti-alpha5beta1 antibodies and uses thereof
WO2011031870A1 (fr) 2009-09-09 2011-03-17 Centrose, Llc Conjugués médicamenteux ciblés à visée extracellulaire
TR201806936T4 (tr) 2010-01-29 2018-06-21 Chugai Pharmaceutical Co Ltd Anti-dll3 antikoru.
CA2787657A1 (fr) 2010-02-23 2011-09-01 Genentech, Inc. Compositions et methodes pour le diagnostic et le traitement d'une tumeur
MA34277B1 (fr) 2010-04-15 2013-06-01 Spirogen Developments Sarl Pyrrolobenzodiazépines et conjugués de celles-ci
MX336540B (es) 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
CN103313990B (zh) 2010-11-17 2016-07-20 基因泰克公司 丙氨酰美登醇抗体偶联物
KR101992502B1 (ko) 2011-05-12 2019-06-24 제넨테크, 인크. 프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법
ES2556584T3 (es) 2011-10-14 2016-01-19 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
PL2814844T3 (pl) 2012-02-15 2017-12-29 Novo Nordisk A/S Przeciwciała wiążące i blokujące receptor aktywujący wykazujący ekspresję na komórkach szpikowych -1 (trem-1)
EP2814842B1 (fr) 2012-02-15 2018-08-22 Novo Nordisk A/S Anticorps liant peptidoglycane reconnaissance protéine 1
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
JP2015529656A (ja) 2012-08-02 2015-10-08 ジェネンテック， インコーポレイテッド 抗ｅｔｂｒ抗体および免疫複合体
CN104717979A (zh) 2012-08-02 2015-06-17 基因泰克公司 抗etbr抗体和免疫偶联物
WO2014057074A1 (fr) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazépines et leurs conjugués
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
PT2906251T (pt) 2012-10-12 2017-12-04 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpo anti-cd22
DK2906296T3 (en) 2012-10-12 2018-05-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2014057120A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués anticorps - pyrrolobenzodiazépine
LT2906253T (lt) 2012-10-12 2018-10-10 Adc Therapeutics Sa Pirolobenzodiazepino-anti-psma antikūno konjugatas
PL2906298T3 (pl) 2012-10-12 2019-04-30 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina - przeciwciało
CN110627797A (zh) 2012-12-21 2019-12-31 麦迪穆有限责任公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
EA031585B1 (ru) 2012-12-21 2019-01-31 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
EA027910B1 (ru) 2013-03-13 2017-09-29 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
CN105209077B (zh) 2013-03-13 2019-06-11 麦迪穆有限责任公司 吡咯并苯并二氮杂卓以及其结合物
PL2970473T3 (pl) 2013-03-14 2018-01-31 Bristol Myers Squibb Co Kombinacja agonisty dr5 i antagonisty anty-pd-1 oraz metody stosowania
CN105636612B (zh) 2013-08-12 2020-01-14 基因泰克公司 抗体-药物缀合物及使用和治疗方法
EP3054983B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépines
EP3054986B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052534A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
CN107106700B (zh) 2013-12-16 2020-10-30 基因泰克公司 肽模拟化合物及其抗体-药物缀合物
CA2928952A1 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composes peptidomimetiques et conjugues anticorps-medicament de ceux-ci
WO2016009086A1 (fr) 2014-07-17 2016-01-21 Novo Nordisk A/S Mutagenèse dirigée d'anticorps trem-1 pour réduire la viscosité
EP3193940A1 (fr) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
TW201625688A (zh) 2014-09-12 2016-07-16 建南德克公司 經半胱胺酸改造之抗體及接合物
WO2016040825A1 (fr) 2014-09-12 2016-03-17 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
CN107073136A (zh) 2014-09-17 2017-08-18 健泰科生物技术公司 吡咯并苯并二氮杂卓及其抗体二硫化物偶联物
KR20170101895A (ko) 2014-11-25 2017-09-06 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 접합체
CA2969689A1 (fr) 2014-12-03 2016-06-09 Genentech, Inc. Composes d'amine quaternaire et conjugues anticorps-medicament de ceux-ci
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (fr) 2016-05-20 2017-11-23 Genentech, Inc. Conjugués anticorps-protac et procédés d'utilisation
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
CN109476648B (zh) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 司维司群抗体-药物缀合物和使用方法
WO2018031662A1 (fr) 2016-08-11 2018-02-15 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CA3047683C (fr) 2017-02-08 2020-03-10 Adc Therapeutics Sa Conjugues anticorps-pyrrolobenzodiazepine
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
AU2018255876B2 (en) 2017-04-18 2020-04-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
US20200129637A1 (en) 2017-04-20 2020-04-30 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
UA127900C2 (uk) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Схема дозування для введення adc до cd19
EP3668874B1 (fr) 2017-08-18 2021-12-22 Medimmune Limited Conjugués de pyrrolobenzodiazépine
AU2018337815A1 (en) 2017-09-20 2020-03-12 Ph Pharma Co., Ltd. Thailanstatin analogs
TWI817974B (zh) 2017-12-28 2023-10-11 日商中外製藥股份有限公司 細胞毒性誘導治療劑
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
JOP20200240A1 (ar) 2018-04-02 2020-09-27 Bristol Myers Squibb Co أجسام مضادة ضد- trem-1 واستخداماتها
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CN113056287A (zh) 2018-10-24 2021-06-29 豪夫迈·罗氏有限公司 缀合的化学降解诱导剂及使用方法
EP3894427A1 (fr) 2018-12-10 2021-10-20 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
BR112021018260A2 (pt) 2019-03-15 2021-11-23 Medimmune Ltd Dímeros de azetidobenzodiazepina e conjugados compreendendo-os para uso no tratamento de câncer
AU2021250186A1 (en) 2020-03-31 2022-12-01 Chugai Seiyaku Kabushiki Kaisha DLL3-targeting multispecific antigen-binding molecules and uses thereof
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
TW202241925A (zh) * 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
CN114113603B (zh) * 2021-06-30 2023-11-17 四川大学华西医院 Cytl1作为胃癌预后标志物的应用
TW202432187A (zh) 2022-12-23 2024-08-16 美商建南德克公司 小腦蛋白降解劑結合物及其用途
WO2024220546A2 (fr) 2023-04-17 2024-10-24 Peak Bio, Inc. Anticorps et conjugués anticorps-médicament et procédés d'utilisation, processus synthétiques et intermédiaires

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
US6194158B1 (en) * 1998-11-12 2001-02-27 Nyxis Neurotherapies, Inc. Diagnostic assay for cancer
US6426186B1 (en) * 2000-01-18 2002-07-30 Incyte Genomics, Inc Bone remodeling genes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GRAWUNDER U ET AL: "Interferon-gamma arrests proliferation and causes apoptosis in stromal cell/interleukin-7-dependent normal murine pre-B cell lines and clones in vitro, but does not induce differentiation to surface immunoglobulin-positive B cells.", EUROPEAN JOURNAL OF IMMUNOLOGY. FEB 1993, vol. 23, no. 2, February 1993 (1993-02-01), pages 544 - 551, XP009053201, ISSN: 0014-2980 *

Also Published As

Publication number Publication date
AU2002330039A1 (en) 2003-04-01
JP2005518782A (ja) 2005-06-30
EP1434881A2 (fr) 2004-07-07
WO2003025138A3 (fr) 2003-05-08
CA2459219A1 (fr) 2003-03-27
WO2003025138A2 (fr) 2003-03-27

Similar Documents

Publication Publication Date Title
EP1434881A4 (fr) Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer
AU2002245317A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
AU2002309583A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002347428A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2002215345A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
AU3491001A (en) Compositions and methods for the early diagnosis of ovarian cancer
AU3983201A (en) Compositions and methods for the early diagnosis of ovarian cancer
WO2002068677A8 (fr) Nouveaux procedes de diagnostic du cancer colorectal metastatique, compositions et procedes de criblage des modulateurs du cancer colorectal metastatique
AU2001231199A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
AU2002251844A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2002257004A1 (en) Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
PL349322A1 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
AU2002249871A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
EP1317669A4 (fr) Procede de diagnostic du cancer colono-rectal et compositions et procedes de criblage de modulateurs du cancer colono-rectal
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
AU2001252945A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
EP1476067A4 (fr) Compositions et procedes contre le cancer
EP1509539A4 (fr) Compositions et procedes concernant le cancer
IL145397A0 (en) Compositions and methods for treatment of cancer
EP1469769A4 (fr) Nouvelles compositions et methodes contre le cancer
EP1349485A4 (fr) Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
PL368035A1 (en) Compositions and methods for the treatment of cancer
AU2002313726A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040324

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050913

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060419